Shetty D, Mashelkar A, Sharan A, S S. Small cell neuroendocrine tumor of the urinary bladder: A case report.
Int J Surg Case Rep 2025;
128:111045. [PMID:
39956028 PMCID:
PMC11872404 DOI:
10.1016/j.ijscr.2025.111045]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2024] [Revised: 02/06/2025] [Accepted: 02/09/2025] [Indexed: 02/18/2025] Open
Abstract
INTRODUCTION AND IMPORTANCE
Bladder cancer is predominantly characterized by urothelial carcinomas, but small cell neuroendocrine carcinomas (SCNEC) represent a rare and aggressive subset.
CASE PRESENTATION
A 50-year-old male presented with painless hematuria and voiding difficulties. Ultrasonography revealed a 3.2 × 3 × 1.8 cm lesion with irregular margins and microcalcifications in the bladder. Computed tomography urography suggested an intra-vesical protruding mass. The patient underwent transurethral resection of the bladder tumor (TURBT). Histopathological examination confirmed SCNEC and papillary urothelial neoplasm of low malignant potential (PUNLMP), with high Ki-67 (90 %). PET-CT ruled out metastasis. Treatment included chemotherapy followed by radiotherapy.
CLINICAL DISCUSSION
At one-year follow-up, the patient was undergoing radiotherapy after completing chemotherapy. This case highlights the importance of multimodal treatment for aggressive bladder cancers, emphasizing TURBT, adjuvant chemotherapy, and radiotherapy.
CONCLUSION
Comprehensive management, including chemotherapy and radiotherapy, is critical in treating rare and aggressive bladder cancers like SCNEC, leading to improved outcomes.
Collapse